CF102 Decreases HCV Viral Load In Liver Cancer Patient: Can-Fite BioPharma
The Phase 1/2 study is recruiting patients with advanced or treatment-refractory HCC. Patients in this trial are tested at entry for infection with hepatitis C virus (HCV). Although
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.